中文摘要：

目的：观察瑞舒伐他汀对高血压合并高胆固醇血症患者血清高敏C反应蛋白（hi—sensitiveC—reactiveprotein，hs—CRP）水平的影响。方法：选择60例高血压合并高胆固醇血症的患者为研究对象，将其随机分为瑞舒伐他汀治疗组（实验组）和常规方法治疗组（对照组），对照组仅给予常规治疗，实验组在常规组治疗的基础上每日加服一次瑞舒伐他汀10mg，疗程8周，测定和比较两组患者治疗前后血压、血清总胆固醇（Totalcholesterol，TC）、低密度脂蛋白胆固醇（Lowdensitylipoprotein—cholesterol，LDL-C）和hs-CRP的水平。结果：治疗8周后，实验组患者的血清SBP、DBP、TC、LDL-C、hs-CRP水平均较治疗前明显降低（P〈0．05），且较对照组组更低（P〈0．05）。结论：瑞舒伐他汀辅助治疗能显著降低高血压合并高胆固醇血症患者的血压和血清血脂水平，并可减少血清高敏c反应蛋白水平，有益于改善患者的预后。

英文摘要：

Objective： To observe the effects of Rosuvastatin on plasma levels of Hi-sensitive C-reactive protein （hs-CRP） in patients with essential hypertension and hypercholesterolemia. Methods： 60 patients of essential hypertension and hypercholesterolemia were selected and randomly divided into two groups： Rosuvastatin treatment group （observation group） and the conventional treatment group （control group）. The patients in observation group were treated with Rosuvastain 10 mg/day besides conventional therapy; the patients in control group were treated only with conventional therapy. The change of Blood pressure, total cholesterol （TC）, Low density lipoprotein-cholesterol （LDL-C） and hs-CRP were determination and comparison before and after 8 weeks treatment. Results： The plasma levels of SBP, DBP, TC, LDL-C and hs-CRP in observation group were decreased significantly （P〈0.01 or P〈0.05） after 8 weeks. The plasma levels of SBP, DBP, TC, LDL-C and hs-CRP in observation group were lower than control group after 8 weeks treatment（P〈0.01 or P〈0.05）. Conclusion： Rosuvastatin adjuvant therapy can significantly lower blood pressure and lipid levels of patients with hypertension and hypercholesterolemia, can reduce serum hs-CRP levels, and can help to improve the prognosis of patients.